Literature DB >> 33925714

Effects of High Glucose Concentration on Pericyte-Like Differentiated Human Adipose-Derived Mesenchymal Stem Cells.

Giuliana Mannino1, Anna Longo1, Florinda Gennuso1, Carmelina Daniela Anfuso1, Gabriella Lupo1, Giovanni Giurdanella1, Rosario Giuffrida1, Debora Lo Furno1.   

Abstract

A pericyte-like differentiation of human adipose-derived mesenchymal stem cells (ASCs) was tested in in vitro experiments for possible therapeutic applications in cases of diabetic retinopathy (DR) to replace irreversibly lost pericytes. For this purpose, pericyte-like ASCs were obtained after their growth in a specific pericyte medium. They were then cultured in high glucose conditions to mimic the altered microenvironment of a diabetic eye. Several parameters were monitored, especially those particularly affected by disease progression: cell proliferation, viability and migration ability; reactive oxygen species (ROS) production; inflammation-related cytokines and angiogenic factors. Overall, encouraging results were obtained. In fact, even after glucose addition, ASCs pre-cultured in the pericyte medium (pmASCs) showed high proliferation rate, viability and migration ability. A considerable increase in mRNA expression levels of the anti-inflammatory cytokines transforming growth factor-β1 (TGF-β1) and interleukin-10 (IL-10) was observed, associated with reduction in ROS production, and mRNA expression of pro-inflammatory cytokines interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), and angiogenic factors. Finally, a pmASC-induced better organization of tube-like formation by retinal endothelial cells was observed in three-dimensional co-culture. The pericyte-like ASCs obtained in these experiments represent a valuable tool for the treatment of retinal damages occurring in diabetic patients.

Entities:  

Keywords:  diabetic retinopathy; eye diseases; high glucose; human adipose mesenchymal stem cells; pericyte-like differentiation; regenerative medicine

Year:  2021        PMID: 33925714     DOI: 10.3390/ijms22094604

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  36 in total

1.  Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier.

Authors:  Stephen J Giebel; Gina Menicucci; Paul G McGuire; Arup Das
Journal:  Lab Invest       Date:  2005-05       Impact factor: 5.662

2.  Interleukin-10 overexpression improves the function of endothelial progenitor cells stimulated with TNF-α through the activation of the STAT3 signaling pathway.

Authors:  Ying Wang; Qingzhong Chen; Zhuhong Zhang; Feng Jiang; Xiangda Meng; Hua Yan
Journal:  Int J Mol Med       Date:  2014-12-11       Impact factor: 4.101

Review 3.  Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress.

Authors:  Ehsan Dehdashtian; Saeed Mehrzadi; Bahman Yousefi; Azam Hosseinzadeh; Russel J Reiter; Majid Safa; Habib Ghaznavi; Masood Naseripour
Journal:  Life Sci       Date:  2017-12-05       Impact factor: 5.037

4.  Critical role of TXNIP in oxidative stress, DNA damage and retinal pericyte apoptosis under high glucose: implications for diabetic retinopathy.

Authors:  Takhellambam S Devi; Ken-Ichi Hosoya; Tetsuya Terasaki; Lalit P Singh
Journal:  Exp Cell Res       Date:  2013-01-24       Impact factor: 3.905

5.  Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes.

Authors:  Deepti Navaratna; Paul G McGuire; Gina Menicucci; Arup Das
Journal:  Diabetes       Date:  2007-05-29       Impact factor: 9.461

6.  Microglia modulation by TGF-β1 protects cones in mouse models of retinal degeneration.

Authors:  Sean K Wang; Yunlu Xue; Constance L Cepko
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 19.456

Review 7.  Stem cell treatment of degenerative eye disease.

Authors:  Ben Mead; Martin Berry; Ann Logan; Robert A H Scott; Wendy Leadbeater; Ben A Scheven
Journal:  Stem Cell Res       Date:  2015-02-24       Impact factor: 2.020

Review 8.  The limited application of stem cells in medicine: a review.

Authors:  Jordan Poulos
Journal:  Stem Cell Res Ther       Date:  2018-01-02       Impact factor: 6.832

9.  Pericyte-like differentiation of human adipose-derived mesenchymal stem cells: An in vitro study.

Authors:  Giuliana Mannino; Florinda Gennuso; Giovanni Giurdanella; Federica Conti; Filippo Drago; Salvatore Salomone; Debora Lo Furno; Claudio Bucolo; Rosario Giuffrida
Journal:  World J Stem Cells       Date:  2020-10-26       Impact factor: 5.326

Review 10.  The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine.

Authors:  Lijun Chen; Jingjing Qu; Charlie Xiang
Journal:  Stem Cell Res Ther       Date:  2019-01-03       Impact factor: 6.832

View more
  4 in total

Review 1.  Therapeutic Potential of Exosomes Derived from Adipose Tissue-Sourced Mesenchymal Stem Cells in the Treatment of Neural and Retinal Diseases.

Authors:  Carl Randall Harrell; Vladislav Volarevic; Valentin Djonov; Ana Volarevic
Journal:  Int J Mol Sci       Date:  2022-04-19       Impact factor: 6.208

2.  The Anti-Inflammatory Effect of the β1-Adrenergic Receptor Antagonist Metoprolol on High Glucose Treated Human Microvascular Retinal Endothelial Cells.

Authors:  Giovanni Giurdanella; Anna Longo; Alfio Distefano; Melania Olivieri; Martina Cristaldi; Alessia Cosentino; Aleksandra Agafonova; Nunzia Caporarello; Gabriella Lupo; Carmelina Daniela Anfuso
Journal:  Cells       Date:  2021-12-24       Impact factor: 6.600

Review 3.  Adipose Tissue-Derived Mesenchymal Stem/Stromal Cells and Their Contribution to Angiogenic Processes in Tissue Regeneration.

Authors:  Agnieszka Krawczenko; Aleksandra Klimczak
Journal:  Int J Mol Sci       Date:  2022-02-22       Impact factor: 5.923

Review 4.  Experiment-Based Interventions to Diabetic Retinopathy: Present and Advances.

Authors:  Siwei Liu; Yahan Ju; Ping Gu
Journal:  Int J Mol Sci       Date:  2022-06-23       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.